These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35141008)

  • 1. De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.
    Ou-Yang F; Li CL; Chen CC; Shen YC; Moi SH; Luo CW; Xia WY; Wang YN; Lee HH; Wang LH; Wang SC; Pan MR; Hou MF; Hung MC
    Am J Cancer Res; 2022; 12(1):123-137. PubMed ID: 35141008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer.
    Ameri A; Tavakoli-Far B; Rostami M; Abedi Kiasari B; Sakhaei D; Saad Ahmed O; Forouzani F; Fazli Y
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109334. PubMed ID: 36327869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
    Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
    N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    Emens LA; Molinero L; Loi S; Rugo HS; Schneeweiss A; Diéras V; Iwata H; Barrios CH; Nechaeva M; Nguyen-Duc A; Chui SY; Husain A; Winer EP; Adams S; Schmid P
    J Natl Cancer Inst; 2021 Aug; 113(8):1005-1016. PubMed ID: 33523233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
    Mavratzas A; Seitz J; Smetanay K; Schneeweiss A; Jäger D; Fremd C
    Future Oncol; 2020 Jan; 16(3):4439-4453. PubMed ID: 31829043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
    Cyprian FS; Akhtar S; Gatalica Z; Vranic S
    Bosn J Basic Med Sci; 2019 Aug; 19(3):227-233. PubMed ID: 30915922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma.
    Roozitalab G; Abedi B; Imani S; Farghadani R; Jabbarzadeh Kaboli P
    Cancer Metastasis Rev; 2024 Sep; 43(3):889-918. PubMed ID: 38409546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
    Narayan P; Wahby S; Gao JJ; Amiri-Kordestani L; Ibrahim A; Bloomquist E; Tang S; Xu Y; Liu J; Fu W; Song P; King-Kallimanis BL; Hou S; Gong Y; Kalavar S; Ghosh S; Philip R; Goldberg KB; Theoret MR; Blumenthal GM; Kluetz PG; Sridhara R; Pazdur R; Beaver JA
    Clin Cancer Res; 2020 May; 26(10):2284-2289. PubMed ID: 32001481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
    Emens LA; Adams S; Barrios CH; Diéras V; Iwata H; Loi S; Rugo HS; Schneeweiss A; Winer EP; Patel S; Henschel V; Swat A; Kaul M; Molinero L; Patel S; Chui SY; Schmid P
    Ann Oncol; 2021 Aug; 32(8):983-993. PubMed ID: 34272041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
    Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
    Kagihara JA; Andress M; Diamond JR
    Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
    Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
    Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R
    Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
    Heeke AL; Tan AR
    Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
    Araujo-Fernandez I; Delgado J; Moscetti L; Sarac SB; Zander H; Mueller-Egert S; Dunder K; Pean E; Bergmann L; Enzmann H; Pignatti F
    ESMO Open; 2021 Feb; 6(1):100008. PubMed ID: 33399074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.